InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
16,954.40
(
-0.17%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
83.96
(
0.50%
)
Bitcoin
57,561.16
(
-1.16%
)
Post# of 251670
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Biowatch

Send PM Follow Ignore
Followers 59
Posts 6572
Boards Moderated 1
Alias Born 10/18/2003

Biowatch

Member Level

Re: None

Tuesday, 03/19/2024 11:00:42 AM

Tuesday, March 19, 2024 11:00:42 AM

Post# of 251670
AZN to buy Fusion for $2.4 billion

Transaction includes actinium-based clinical-stage radioconjugate targeting PSMA for prostate cancer, pipeline of radioconjugates and state-of-the-art R&D and manufacturing facilities

Fusion shareholders to receive $21.00 per share in cash at closing plus a non-transferrable contingent value right (CVR) of $3.00 per share, representing a total transaction value of approximately $2.4 billion including the CVR


https://finance.yahoo.com/news/fusion-pharmaceuticals-acquired-astrazeneca-accelerating-070000564.html
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up